{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T13:15:40Z","timestamp":1791378940046,"version":"4.3.2"},"reference-count":30,"publisher":"MedWorks Media","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacol Bull"],"abstract":"<jats:p>Introduction\nBenzodiazepines are currently the gold standard for treatment of alcohol withdrawal. Gabapentin has growing evidence to support its use in the treatment of alcohol use disorder, however there is limited evidence regarding its role in the treatment of alcohol withdrawal. The purpose of this study was to determine if adjunctive gabapentin reduces the need for benzodiazepine (BZD) administration during alcohol withdrawal.\nMethods\nThis was a retrospective single-center cohort study. Patients were included if they were 18\u201389 years old, had an underlying alcohol use disorder, and were initiated on the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) protocol with or without scheduled gabapentin. They were excluded if they had a BZD use disorder, were on concomitant anti-epileptics, as-needed gabapentin, or BZDs outside the CIWA-Ar protocol.\nResults\nA total of 129 patients met inclusion criteria (n = 63 gabapentin group and 66 non-gabapentin group). There was a significant difference in as-needed BZD requirements, with the gabapentin group requiring a higher number of as-needed BZDs in the initial 72 hours of treatment (gabapentin 6 [IQR 0.5\u201310] non-gabapentin 2 [IQR 0\u20134]; p = 0.01) and overall (gabapentin 6 [IQR 0.5\u201310] vs. non-gabapentin 2 [IQR 0\u20135.5]; p = 0.01). The gabapentin group also had higher maximum CIWA-Ar scores in the initial 72 hours of treatment, and higher anxiety item scores in the initial 48 hours.\nConclusion\nGabapentin was not shown to reduce as-needed BZD requirements in patients with a diagnosis of alcohol use disorder admitted for alcohol withdrawal.<\/jats:p>","DOI":"10.64719\/pb.4587","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T11:39:16Z","timestamp":1761046756000},"page":"17-27","source":"Crossref","is-referenced-by-count":2,"title":["Impact of Gabapentin Adjunct use with Benzodiazepines for the Treatment of Alcohol Withdrawal in a Psychiatric Hospital"],"prefix":"10.64719","volume":"49","author":[{"given":"Nina","family":"Vadiei","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tawny L.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy E.","family":"Walton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly L.","family":"Kjome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54175","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Sachdeva A, Chondhary M, Chandra M. Alcohol Withdrawal Syndrome: Benzodiazepines and Beyond. J Clin Diagn Res. 2015;9(9):VE01\u2013VE07.","DOI":"10.7860\/JCDR\/2015\/13407.6538"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Amato L, Minozzi S, Vecchi S, Davoli M. Benzodiazepines for alcohol withdrawal. Cochrane Database Syst Rev. 2010;3:CD005063.","DOI":"10.1002\/14651858.CD005063.pub3"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Poulos CX, Zack M. Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers. Behav Pharmacol. 2004;15(7):503\u2013512.","DOI":"10.1097\/00008877-200411000-00006"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Malcolm R, Myrick H, Roberts J, Wang W, Anton RF, Ballenger JC. The effects of carbamazepine and lorazepam on single versus multiple previous alcohol withdrawals in an outpatient randomized trial. J Gen Intern Med. 2002;17(5):349\u2013355.","DOI":"10.1007\/s11606-002-0038-1"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Myrick H, Malcolm R, Randall PK. A double-blind trial of gabapentin versus lorazepam in the treatment of alcohol withdrawal. Alcohol Clin Exp Res. 2009;33(9):1582\u20131588.","DOI":"10.1111\/j.1530-0277.2009.00986.x"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Mayo-Smith MF. Pharmacological management of alcohol withdrawal. A meta-analysis and evidence-based practice guideline. American Society of Addiction Medicine Working Group on Pharmacological Management of Alcohol Withdrawal. JAMA. 1997;278(2):144\u2013151.","DOI":"10.1001\/jama.1997.03550020076042"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Caputo F, Bernardi M. Medications Acting on the GABA System in the Treatment of Alcoholic Patients. Curr Pharm Design. 2010;16(19):2118\u20132125.","DOI":"10.2174\/138161210791516468"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Maldonado JR. Delirium in the acute care setting: characteristics, diagnosis and treatment. Crit Care Clinic. 2008;24(4):657\u2013722.","DOI":"10.1016\/j.ccc.2008.05.008"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Lejoyeux M, Solomon J, Ad\u00e8s J. Benzodiazepine treatment for alcohol-dependent patients. Alcohol Alcohol. 1998;33(6):563\u2013575.","DOI":"10.1093\/alcalc\/33.6.563"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Perry EC. Inpatient management of acute alcohol withdrawal syndrome. CNS Drugs. 2014;28(5):401\u2013410.","DOI":"10.1007\/s40263-014-0163-5"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Minozzi S, Amato L, Vecchi S, Davoli M. Anticonvulsants for alcohol withdrawal. Cochrane Database Syst Rev. 2010;3:CD005064.","DOI":"10.1002\/14651858.CD005064.pub3"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Watson WP, Robinson E, Little HJ. The novel anticonvulsant, gabapentin, protects against both convulsant and anxiogenic aspects of the ethanol withdrawal system. Neuropharmacology. 1997;36(10):1369\u20131375.","DOI":"10.1016\/S0028-3908(97)00118-4"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Barrons R, Roberts N. The role of carbamazepine and oxcarbazepine in alcohol withdrawal syndrome. J Clin Pharm Ther. 2010;35(2):153\u2013167.","DOI":"10.1111\/j.1365-2710.2009.01098.x"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Eyer F, Schreckenberg M, Hecht D. Carbamazepine and valproate as adjuncts in the treatment of alcohol withdrawal syndrome: a retrospective cohort study. Alcohol Alcohol. 2011;46(2):177\u2013184.","DOI":"10.1093\/alcalc\/agr005"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Reoux JP, Saxon AJ, Malte CA, Baer JS, Sloan KL. Divalproex sodium in alcohol withdrawal: a randomized double-blind placebo-controlled clinical trial. Alcohol Clin Exp Res. 2001;25(9):1324\u20131329.","DOI":"10.1111\/j.1530-0277.2001.tb02354.x"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Mason BJ, Quello S, Goodell V, Shadan F, Kyle M, Begovic A. Gabapentin treatment for alcohol dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(1):78\u201379.","DOI":"10.1001\/jamainternmed.2013.11950"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Furieri FA, Nakamura-Palacios EM. Gabapentin reduces alcohol consumption and craving: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry. 2007;68(11):1691\u20131700.","DOI":"10.4088\/JCP.v68n1108"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Clemens KJ, Vendruscolo LF. Anxious to drink: gabapentin normalizes GABAergic transmission in the central amygdala and reduces symptoms of ethanol dependence. J Neurosci. 2008;28(37):9087\u20139089.","DOI":"10.1523\/JNEUROSCI.2928-08.2008"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Stock CJ, Carpenter L, Ying J, Greene T. Gabapentin versus chlordiazepoxide for outpatient alcohol detoxification treatment. Ann Pharmacother. 2013;47(7-8):961\u2013969.","DOI":"10.1345\/aph.1R751"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Bonnet U, Banger M, Leweke FM, Maschke M, Kowalski T, Gastpar M. Treatment of alcohol withdrawal syndrome with gabapentin. Pharmacopsychiatry. 1999;32(3):107\u2013109.","DOI":"10.1055\/s-2007-979203"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Bonnet U, Banger M, Leweke M. Treatment of Acute Alcohol Withdrawal With Gabapentin: Results From a Controlled Two-Center Trial. J Clin Psychopharmacol. 2003;23(5):514\u2013519.","DOI":"10.1097\/01.jcp.0000088905.24613.ad"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Mariani JJ, Rosenthal RN, Tross S, Singh P, Anand OP. A randomized, open-label, controlled trial of gabapentin and phenobarbital in the treatment of alcohol withdrawal. Am J Addict. 2006;15(1):76\u201384.","DOI":"10.1080\/10550490500419110"},{"key":"ref23","doi-asserted-by":"crossref","unstructured":"Bonnet U, Hamzavi-Abedi R, Specka M, Wiltfang J, Lieb B, Scherbaum N. An open trial of gabapentin in acute alcohol withdrawal using an oral loading protocol. Alcohol Alcohol. 2010;45(2):143\u2013145.","DOI":"10.1093\/alcalc\/agp085"},{"key":"ref24","doi-asserted-by":"crossref","unstructured":"Leung JG, Rakocevic DB, Allen ND. Use of a Gabapentin Protocol for the Management of Alcohol Withdrawal: A Preliminary Experience Expanding From the Consultation-Liaison Psychiatry Service. Psychosomatics. 2018;S0033-3182(18):30138\u20135.","DOI":"10.1016\/j.psym.2018.03.002"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Kosten TR, O\u2019Connor PG. Management of drug and alcohol withdrawal. N Engl J Med. 2003;348(18):1786\u20131795.","DOI":"10.1056\/NEJMra020617"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Hammond CJ, Niciu MJ, Drew S, Arias AJ. Anticonvulsants for the treatment of alcohol withdrawal syndrome and alcohol use disorders. CNS Drugs. 2015;29(4):293\u2013311.","DOI":"10.1007\/s40263-015-0240-4"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Leung JG, Hall-Flavin D, Nelson S, Schmidt KA, Schak KM. The role of gabapentin in the management of alcohol withdrawal and dependence. Ann Pharmacother. 2015;49(8):897\u2013906.","DOI":"10.1177\/1060028015585849"},{"key":"ref28","unstructured":"Bezchlibnyk-Butler KZ, Jeffries JJ, editors. 4th. Toronto: Hogrefe & Huber; 1991. Clinical Handbook of Psychotropic Drugs. revised edition. Clarke Institute of Psychiatry."},{"key":"ref29","unstructured":"What is a standard drink? National Institute on Alcohol Abuse and Alcoholism (NIAAA) Alcohol & Your Health website. 2018 Mar 13; https:\/\/www.niaaa.nih.gov\/alcohol-health\/overview-alcohol-consumption\/what-standard-drink. Accessed."},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Maldonado JR, Sher Y, Ashouri JF. The \u201cPrediction of Alcohol Withdrawal Severity Scale\u201d (PAWSS): systematic literature review and pilot study of a new scale for the prediction of complicated alcohol withdrawal syndrome. Alcohol. 2014;48(4):375\u2013390.","DOI":"10.1016\/j.alcohol.2014.01.004"}],"container-title":["Psychopharmacology Bulletin"],"original-title":[],"deposited":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T19:35:00Z","timestamp":1791315300000},"score":1,"resource":{"primary":{"URL":"https:\/\/medworksmedia.com\/pb-article\/impact-of-gabapentin-adjunct-use-with-benzodiazepines-for-the-treatment-of-alcohol-withdrawal-in-a-psychiatric-hospital\/"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,8,12]]}},"URL":"https:\/\/doi.org\/10.64719\/pb.4587","relation":{},"ISSN":["2472-2448"],"issn-type":[{"value":"2472-2448","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}